Publications by authors named "David Tetard"

Claim this Profile
N
Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines.
Gina Abdelaal, Andrew Carter, William Cheung, Mihalis Panayiotidis, Seth Racey

Biomedicines· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines.
Gina Abdelaal, Andrew Carter, Mihalis I Panayiotides, David Tetard, Stephany Veuger

Front Mol Biosci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-Hydroxy-2(1)-pyridinone-Based Chelators with Potential Catechol -Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson's Disease.
Joseph C J Bergin, Kean Kan Tan, Anya K Nelson, Cristina-Andreea Amarandei, Véronique Hubscher-Bruder

Molecules· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1)-one iron chelators in an cell model of Parkinson's disease.
Frank W Lewis, Kathleen Bird, Jean-Philippe Navarro, Rawa El Fallah, Jeremy Brandel

Dalton Trans· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma.
Sotiris Kyriakou, William Cheung, Theodora Mantso, Melina Mitsiogianni, Ioannis Anestopoulos, David Tetard

Invest New Drugs· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants.
Simon Gutbier, Sotiris Kyriakou, Stefan Schildknecht, Anna-Katharina Ückert, Markus Brüll, David Tetard

Arch Toxicol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma.
Sotiris Kyriakou, Melina Mitsiogianni, Theodora Mantso, William Cheung, Stephen Todryk, David Tetard

Invest New Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Frank W Lewis, Safiya Fairooz, Joanna L Elson, Véronique Hubscher-Bruder, Jeremy Brandel

Arch Toxicol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of linkages between 1-hydroxy-2(1H)-pyridinone coordinating groups and a tris(2-aminoethyl)amine core in a novel series of synthetic hexadentate iron(III) chelators on antimicrobial activity.
David G Workman, Michael Hunter, Shuning Wang, Jérémy Brandel, Véronique Hubscher

Bioorg Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of novel Iron(III) chelators based on triaza macrocycle backbone and 1-hydroxy-2(H)-pyridin-2-one coordinating groups and their evaluation as antimicrobial agents.
David G Workman, Michael Hunter, Lynn G Dover, David Tétard

J Inorg Biochem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.
David G Workman, Andrew Tsatsanis, Frank W Lewis, John P Boyle, Maryam Mousadoust

Metallomics· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis